Clinical trial · Observational
An Observational Study on the Impact of the 23-valent Pneumonia Vaccine on Lung Cancer Patients
An Observational Study on the Impact of the 23-valent Pneumonia Vaccine on the Incidence of Pulmonary Infection and Survival in Lung Cancer Patients
NCT07142057CI-TRIAL-00094140not yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To evaluate the impact of the 23-valent pneumonia vaccine on the incidence of pulmonary infection and survival in lung cancer patients, and to explore its preventive effect and safety in the lung cancer patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| LUNG CANCER | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 23-valent pneumococcal vaccine | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Vaccination group
- description
- Lung cancer patients receive 23-valent pneumonia vaccine
- interventionNames
- Biological: 23-valent pneumococcal vaccine
- label
- Unvaccinated group
- description
- Lung cancer patients have not received the 23-valent pneumococcal vaccine
Primary outcomes (2)
- measure
- The incidence of pneumonia at 12 months
- timeFrame
- 12 months
- description
- During the 12-month follow-up period, the incidence of pulmonary infection in lung cancer patients was evaluated through regular clinical examinations, imaging tests, and laboratory tests.
- measure
- Incidence of pneumonia
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Male or female patients \>=18 years of age; 2. Histological diagnosis of NSCLC, including both non-small cell lung cancer and small cell lung cancer, regardless of whether they are in the early, locally advanced stage or advanced stage, and regardless of whether they have received surgery, radiotherapy, chemotherapy or other treatments; 3. Never received pneumococcal vaccine Exclusion Criteria: Patients having other factors that preventing researchers from enrollment them.
References
Publications (0)
Data not yet available
No reference posted for this study.